Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms

C

Catherine Buettner

Status and phase

Completed
Phase 3
Phase 2

Conditions

HMG COA Reductase Inhibitor Adverse Reaction
Weakness
Cramps
Myalgia or Myositis Nos
Pain

Treatments

Other: Placebo
Dietary Supplement: Coenzyme Q10

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT01032993
K23AR055664 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study will evaluate whether a dietary supplement, coenzyme Q10 (CoQ10), will improve muscle symptoms, such as muscle aches, pains, cramps, and/or weakness, which are experienced by some individuals who use statin medications.

Full description

This study will recruit individuals who have had muscle symptoms while using a statin. During the first part of the study, volunteers will be given a statin medication to see if their muscle symptoms return. Those who experience muscle symptoms on this statin rechallenge will be invited to continue in the second part of the trial, in which participants will be randomly assigned to receive either CoQ10 or a placebo (sugar pill) to take with statin medication. We hypothesize that those who receive CoQ10 will experience an improvement in their muscle symptoms compared to those who receive placebo, and, secondarily, that those who receive CoQ10 will be more likely to continue taking the statin medication.

Enrollment

68 patients

Sex

All

Ages

21+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients with a history of muscle symptoms (such as aches, pains, cramps and/or weakness) while taking a statin drug that persisted for at least 2 weeks on a statin

Exclusion criteria

  • Plasma creatine kinase levels > 3 times the upper normal limit
  • Liver enzymes, alanine transferase (ALT) or aspartate transferase (AST) > 2 times the upper normal limit
  • Pregnancy or breastfeeding (a contraindication for statin use)
  • Severe renal impairment, defined as glomerular filtration rate (GFR) < 30 ml/min/1.73 m2
  • Bleeding disorder, current use of warfarin, an international normalized ratio (INR) greater than 1.5, or a platelet count less than 100,000 mm3
  • Contraindication to strength testing, including myocardial infarction, unstable angina, or revascularization procedure within the past six weeks, a history of brain aneurysm or stroke
  • Chest or abdominal surgery within the past six weeks
  • Severe persistent pain related to other causes
  • Unable to complete self-administered questionnaires, or unable to read or converse in English

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

68 participants in 2 patient groups, including a placebo group

Coenzyme Q10
Active Comparator group
Description:
600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
Treatment:
Dietary Supplement: Coenzyme Q10
Placebo
Placebo Comparator group
Description:
Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
Treatment:
Other: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems